Latest Avidity Partners Management LP Stock Portfolio
$2.35Billion– No. of Holdings #85
Avidity Partners Management LP Performance:
2024 Q2: -2.55%YTD: 6.76%2023: 6.74%
Performance for 2024 Q2 is -2.55%, and YTD is 6.76%, and 2023 is 6.74%.
About Avidity Partners Management LP and 13F Hedge Fund Stock Holdings
Avidity Partners Management LP is a hedge fund based in DALLAS, TX. On 31-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $9.2 Billions. In it's latest 13F Holdings report, Avidity Partners Management LP reported an equity portfolio of $2.4 Billions as of 30 Jun, 2024.
The top stock holdings of Avidity Partners Management LP are ISRG, BSX, NTRA. The fund has invested 4.6% of it's portfolio in INTUITIVE SURGICAL INC and 3.8% of portfolio in BOSTON SCIENTIFIC CORP.
The fund managers got completely rid off FUSION PHARMACEUTICALS INC (FUSN), ALIGN TECHNOLOGY INC (ALGN) and ELI LILLY & CO (LLY) stocks. They significantly reduced their stock positions in NUVATION BIO INC (NUVB), AC IMMUNE SA and KARYOPHARM THERAPEUTICS INC (KPTI). Avidity Partners Management LP opened new stock positions in INCYTE CORP (INCY), PERSPECTIVE THERAPEUTICS INC and INSMED INC (INSM). The fund showed a lot of confidence in some stocks as they added substantially to BIOHAVEN LTD, ESTABLISHMENT LABS HLDGS INC (ESTA) and COGENT BIOSCIENCES INC (COGT).
The top stock holdings of Avidity Partners Management LP are ISRG, BSX, NTRA. The fund has invested 4.6% of it's portfolio in INTUITIVE SURGICAL INC and 3.8% of portfolio in BOSTON SCIENTIFIC CORP.
The fund managers got completely rid off FUSION PHARMACEUTICALS INC (FUSN), ALIGN TECHNOLOGY INC (ALGN) and ELI LILLY & CO (LLY) stocks. They significantly reduced their stock positions in NUVATION BIO INC (NUVB), AC IMMUNE SA and KARYOPHARM THERAPEUTICS INC (KPTI). Avidity Partners Management LP opened new stock positions in INCYTE CORP (INCY), PERSPECTIVE THERAPEUTICS INC and INSMED INC (INSM). The fund showed a lot of confidence in some stocks as they added substantially to BIOHAVEN LTD, ESTABLISHMENT LABS HLDGS INC (ESTA) and COGENT BIOSCIENCES INC (COGT).
Avidity Partners Management LP Equity Portfolio Value
Last Reported on: 14 Aug, 2024
Avidity Partners Management LP Annual Return Estimates Vs S&P 500
Our best estimate is that Avidity Partners Management LP made a return of -2.55% in the last quarter. In trailing 12 months, it's portfolio return was 16.77%.
New Buys
| Ticker | $ Bought |
|---|---|
| incyte corp | 32,068,000 |
| perspective therapeutics inc | 30,285,600 |
| insmed inc | 28,810,000 |
| cullinan therapeutics inc | 27,203,400 |
| argenx se | 26,017,400 |
| gilead sciences inc | 17,495,600 |
| sanofi | 15,283,800 |
| context therapeutics inc | 14,875,800 |
New stocks bought by Avidity Partners Management LP
Additions
| Ticker | % Inc. |
|---|---|
| biohaven ltd | 500 |
| establishment labs hldgs inc | 136 |
| cogent biosciences inc | 124 |
| janux therapeutics inc | 118 |
| thermo fisher scientific inc | 118 |
| immunovant inc | 79.8 |
| keros therapeutics inc | 63.66 |
| neurogene inc | 56.38 |
Additions to existing portfolio by Avidity Partners Management LP
Reductions
| Ticker | % Reduced |
|---|---|
| nuvation bio inc | -86.45 |
| ac immune sa | -81.54 |
| karyopharm therapeutics inc | -75.68 |
| collegium pharmaceutical inc | -67.63 |
| prime medicine inc | -65.13 |
| united therapeutics corp del | -49.31 |
| legend biotech corp | -40.45 |
| boston scientific corp | -40.18 |
Avidity Partners Management LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| fusion pharmaceuticals inc | -138,587,000 |
| caribou biosciences inc | -29,736,700 |
| ginkgo bioworks holdings inc | -3,480,000 |
| x4 pharmaceuticals inc | -3,354,070 |
| emergent biosolutions inc | -4,827,240 |
| century therapeutics inc | -5,106,100 |
| alpine immune sciences inc | -46,565,100 |
| an2 therapeutics inc | -3,737,500 |
Avidity Partners Management LP got rid off the above stocks
Sector Distribution
Avidity Partners Management LP has about 81.6% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 81.6 |
| Others | 15.5 |
| Basic Materials | 2.8 |
Market Cap. Distribution
Avidity Partners Management LP has about 42.8% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| LARGE-CAP | 37.2 |
| MID-CAP | 23.7 |
| UNALLOCATED | 16.2 |
| SMALL-CAP | 14.6 |
| MEGA-CAP | 5.6 |
| MICRO-CAP | 2.4 |
Stocks belong to which Index?
About 54.6% of the stocks held by Avidity Partners Management LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 45.4 |
| RUSSELL 2000 | 28.7 |
| S&P 500 | 25.9 |
Avidity Partners Management LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Avidity Partners Management LP
Avidity Partners Management LP has 85 stocks in it's portfolio. About 32.9% of the portfolio is in top 10 stocks. ARVN proved to be the most loss making stock for the portfolio. ALNY was the most profitable stock for Avidity Partners Management LP last quarter.
Last Reported on: 14 Aug, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ABBV | abbvie inc | 2.02 | 277,800 | 47,648,300 | added | 22.38 | ||
| ABIO | arca biopharma inc | 0.16 | 1,000,000 | 3,830,000 | new | |||
| ACAD | acadia pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ACHC | acadia healthcare company in | 3.21 | 1,120,000 | 75,644,800 | added | 11.44 | ||
| AGLE | spyre therapeutics inc | 0.20 | 195,000 | 4,584,450 | new | |||
| ALGN | align technology inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ALNY | alnylam pharmaceuticals inc | 2.29 | 222,000 | 53,946,000 | reduced | -8.64 | ||
| ALPN | alpine immune sciences inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ANTX | an2 therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ARVN | arvinas inc | 3.38 | 2,987,840 | 79,536,400 | added | 0.09 | ||
| ATXS | astria therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AVTR | avantor inc | 2.78 | 3,086,000 | 65,423,200 | added | 14.51 | ||
| AXSM | axsome therapeutics inc | 1.29 | 376,000 | 30,268,000 | reduced | -12.76 | ||
| BPMC | blueprint medicines corp | 1.75 | 383,000 | 41,279,700 | reduced | -10.09 | ||
| BSX | boston scientific corp | 3.83 | 1,170,100 | 90,109,400 | reduced | -40.18 | ||
| CGEM | cullinan therapeutics inc | 1.16 | 1,559,830 | 27,203,400 | new | |||
| CI | the cigna group | 2.59 | 184,500 | 60,990,200 | unchanged | 0.00 | ||
| CMAX | caremax inc | 0.00 | 21,200 | 59,148 | unchanged | 0.00 | ||
| CNTX | context therapeutics inc | 0.63 | 7,419,360 | 14,875,800 | new | |||
| COGT | cogent biosciences inc | 0.36 | 1,000,710 | 8,435,950 | added | 124 | ||